GSK Korea ranked in the list of Korea’s Most Admired Companies
10 4월 2018
- GSK topped the list in the foreign pharma industry sector at the 2018 KMAC survey.
GSK Korea ranked first in the foreign pharmaceutical industry sector in the 'Korea' s Most Admired Companies' survey conducted by the Korea Management Association Consulting (KMAC) in 2018. To commemorate the selection, the company held a ceremony for the receival of KMAC's certificate at Seoul office on 9 April.
KMAC, a management consulting and research firm, announces the selection of the best companies as Korea’s Most Admired Companies’ every year since 2004 by using the survey model for comprehensive assessments of the corporate value areas.
For the 2018 selection, the research group conducted the survey on about 800 candidate companies across manufacturing, service and public sectors involving a total of 12,230 people including executives, securities analysts and customers from October 2017 to January this year. The evaluation areas include: ▲Innovation Capabilities ▲Stakeholder Value ▲Employee Value ▲ Customer Value ▲Society Value ▲Brand Image Value.
KMAC determined the rankings of the companies that received the highest scores from various recipients based on the comprehensive evaluation of the six criteria.
GSK Korea, which is pursuing a patient-focused business on the 3 key priorities of innovation, performance and trust, was selected as the top foreign pharmaceutical company in the industry sector.
Kwang-ho Song, Head of the Assessment Division at KMAC, said, “GSK Korea showed a significant year-on-year improvement in all areas including employee value such as investment to train and educate employees, customer value such as customer satisfaction management with quality of products and services, and innovation activities to adapt to change. This is the most important factor in the number of respondents who responded positively to the change. In particular, its innovation activities for change adaptation showed the highest response quality.”
Julien Samson, Korea GM, said, “GSK Korea was very pleased to receive good results from the external survey that evaluated corporate competitiveness from various perspectives. We have been able to be selected as the most admired company, which is currently emerging at the top priority of global company management as our leadership in healthcare and efforts to pursue IPT (innovation, performance and trust) have gained recognition.” He added, “We will strive to be the most trusted healthcare partner who leads innovation and patient-focused business in Korea.”
# # #